Form 4: ATYR Director Boosts Stake with $900K Stock Purchase

Paul Schimmel, a Director at aTYR PHARMA INC, significantly increased his beneficial ownership by purchasing over 1 million shares of common stock.

Summary

• Paul Schimmel, a Director of aTYR PHARMA INC (ATYR), acquired additional common stock through open market purchases.
• On October 8, 2025, Schimmel purchased 682,001 shares of common stock at a weighted average price of $0.898 per share, with prices ranging from $0.8536 to $0.95 per share.
• On October 9, 2025, he acquired an additional 317,999 shares of common stock at a weighted average price of $0.9414 per share, with prices ranging from $0.93 to $0.95 per share.
• The total value of these acquisitions amounts to approximately $911,836.96.
• Following these transactions, Schimmel's indirect beneficial ownership through Paul Schimmel Prototype PSP increased to 1,413,023 shares.
• He also directly owns 8,890 shares and indirectly owns 679,143 shares through the Schimmel Revocable Trust.

Sentiment

Score: 8

Explanation: The significant purchase of over $900,000 worth of common stock by a director indicates strong insider confidence in the company's future prospects, which is generally viewed positively by the market.

Positives

• A Director, Paul Schimmel, made a substantial investment by purchasing over 1 million shares of the company's common stock.
• The total value of the shares acquired exceeded $900,000, signaling strong insider confidence.
• Increased insider ownership often indicates management's belief in the company's future prospects and potential undervaluation.

Future Outlook

NA

Industry Context

Insider buying, particularly by a director, can be interpreted by the market as a positive signal, suggesting management's confidence in the company's future performance. This is often closely watched in the biotechnology and pharmaceutical sectors due to high R&D costs, regulatory hurdles, and the speculative nature of drug development, where insider sentiment can provide valuable cues.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The significant insider buying by a director may instill greater confidence in the company's prospects, potentially leading to a positive market perception and increased investor interest.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Recommendation

The substantial insider buying by a director, Paul Schimmel, who acquired over $900,000 worth of common stock, signals strong confidence in the company's valuation and future prospects. Such a significant investment by an insider, especially a director, often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for investors.

Keywords

ATYR PHARMA INC, ATYR, Paul Schimmel, Insider Buying, Form 4, Director Stock Purchase, Biotechnology, Pharmaceuticals